Killing Tumor Cells with Antibody-Targeted Prodrug Activation
Author Information
Author(s): Cheng T L, Wei S L, Chen B M, Chern J W, Wu M F, Liu P W, Roffler S R
Primary Institution: Institute of Biomedical Sciences, Academia Sinica
Hypothesis
Can antibody-targeted enzymatic activation of a glucuronide prodrug kill bystander tumor cells?
Conclusion
The study found that targeted activation of a prodrug can effectively kill bystander tumor cells in vivo.
Supporting Evidence
- The treatment killed 99% of targeted AS-30D cells without harming N1S1 cells.
- Over 98% of N1S1 cells were killed in mixed populations with as few as 2% AS-30D cells.
- The treatment cured all seven mice with solid AS-30D tumors.
Takeaway
This study shows that a special treatment can help kill cancer cells even if they are not directly targeted, which is like a superhero saving the day for everyone around.
Methodology
The study used a combination of antibody-targeted enzyme and prodrug treatment in both cell cultures and mouse models.
Participant Demographics
The study involved BALB/c nu/nu mice and specific rat hepatoma cell lines.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website